Lexicon Q3 net loss $23.4M; sotagliflozin NDA on track for May 2023; cash $136.2M

LEXICON PHARMACEUTICALS, INC.

2023-Q3 EPS reported -$0.45 revenue$111,000

Net loss of $23.4M ($0.13 per share) vs $23.1M ($0.16) in Q3 2021.
Cash and investments $136.2M at Sep 30, 2022, up from $86.7M at Dec 31, 2021 after $94.3M net proceeds from public offering and private placement.
NDA for sotagliflozin in heart failure accepted, PDUFA target action date May 2023; mid-cycle review meeting completed.
Final data from RELIEF-DPN-1 (LX9211) in painful diabetic neuropathy to be presented; enrollment complete in RELIEF-PHN-1 study with top-line data expected by year-end.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

LEXICON PHARMACEUTICALS, INC. reported the three months ended September 30, 2022 results: net income $23.4 million, or $0.13 per share.

Period: the three months ended September 30, 2022
Net income: $23.4 million, or $0.13 per share
Result: reported results

Exact text from the filing

Net loss for the third quarter of 2022 was $23.4 million, or $0.13 per share, as compared to a net loss of $23.1 million, or $0.16 per share, in the corresponding period in 2021.

View on SEC.gov

Browse all earnings releases →

LEXICON PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001062822-22-000041

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.